These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30386917)

  • 1. Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
    Matsumura K; Morishita S; Taniguchi N; Takehana K; Takahashi H; Otagaki M; Yoshioka K; Yamamoto Y; Takagi M; Shiojima I
    Heart Vessels; 2019 Apr; 34(4):607-615. PubMed ID: 30386917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan.
    Fujioka K; Mizuno S; Ichise T; Matsui T; Hirase H; Yamaguchi M; Aoyama T; Yamagishi M; Fujino N; Kawashiri MA; Hayashi K
    Ther Adv Cardiovasc Dis; 2019; 13():1753944718819064. PubMed ID: 30803403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
    Morita Y; Endo A; Kagawa Y; Yamaguchi K; Sato H; Ouchi T; Watanabe N; Tanabe K
    Heart Vessels; 2021 Jun; 36(6):836-843. PubMed ID: 33527152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T; Li GS
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
    Fukuoka H; Tachibana K; Shinoda Y; Minamisaka T; Inui H; Ueno K; Inoue S; Mine K; Ueda K; Hoshida S
    BMC Cardiovasc Disord; 2020 Oct; 20(1):467. PubMed ID: 33121430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
    Nishino M; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Egami Y; Tanouchi J
    Int Heart J; 2022; 63(1):85-90. PubMed ID: 35095082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.
    Kinoshita M; Okayama H; Kosaki T; Hosokawa S; Kawamura G; Shigematsu T; Takahashi T; Kawada Y; Hiasa G; Yamada T; Matsuoka H; Kazatani Y
    Heart Vessels; 2018 Feb; 33(2):163-169. PubMed ID: 28889231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of sodium level trajectory in acute heart failure.
    Matsue Y; Yoshioka K; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Heart Vessels; 2017 Dec; 32(12):1498-1505. PubMed ID: 28698994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
    Kajimoto K; Otsubo S
    Am J Case Rep; 2019 Jul; 20():1006-1010. PubMed ID: 31296836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan.
    Nomoto H; Satoh Y; Kamiyama M; Yabe K; Masumura M; Sakakibara A; Yamashita S; Suzuki M; Sugiyama T; Oumi T; Ohno M; Takahashi Y; Isobe M
    Int Heart J; 2017 Aug; 58(4):593-600. PubMed ID: 28701677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.